DelveInsight’s, “Phenylketonuria Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Phenylketonuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Phenylketonuria Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Phenylketonuria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Phenylketonuria Pipeline Report
To explore more information on the latest breakthroughs in the Phenylketonuria Pipeline treatment landscape of the report, click here @ Phenylketonuria Pipeline Outlook
Phenylketonuria Overview
Phenylketonuria as known as PKU is a metabolic disorder that can adversely affect the body’s natural homeostatic or steady state and lead to chemical imbalances and severe pathological conditions. Phenylketonuria is such an example in which the normal conversion of the dietary amino acid phenylalanine to tyrosine is blocked.
Recent Developmental Activities in the Phenylketonuria Treatment Landscape
For further information, refer to the detailed Phenylketonuria Unmet Needs, Phenylketonuria Market Drivers, and Phenylketonuria Market Barriers, click here for Phenylketonuria Ongoing Clinical Trial Analysis
Phenylketonuria Emerging Drugs Profile
Sepiapterin (PTC923) is an oral formulation of synthetic sepiapterin, a precursor to intracellular tetrahydrobiopterin, an enzymatic cofactor involved in the metabolism and synthesis of numerous metabolic products. Results from a Phase II clinical trial of CNSA-001 demonstrated significant and clinically relevant reductions in phenylalanine levels compared to current first-line treatment. Previous preclinical and healthy volunteer studies showed that an oral dose of CNSA-001 increased target tissue and plasma tetrahydrobiopterin more effectively than equivalent oral doses of sapropterin dihydrochloride. Since sepiapterin is a more stable molecule and is transported more efficiently across cells, it has the potential to be more effective than Kuvan in boosting PAH activity, reducing phenylalanine levels, and lessening symptoms in PKU patients. In May 2020, PTC Therapeutics announced that it agreed to acquire Censa Pharmaceuticals, focused on developing CNSA-001 (sepiapterin). Sepiapterin is currently being investigated in Phase III stage of development for the treatment of Phenylketonuria.
SYNB1618 is an orally administered Synthetic BioticTM medicines being developed as potential treatments for phenylketonuria (PKU). It is an engineered strain of the microorganism E. coli Nissle that encodes phenylalanine ammonia lyase (PAL), an enzyme that breaks down Phe. It is intended to address the needs of patients of all age groups through the consumption of Phe in the gastrointestinal tract, which has the potential to lower blood Phe levels and enable the consumption of more natural protein in the diet. SYNB1618 has received both Orphan Drug and Fast Track designations by the US Food and Drug Administration (FDA) and orphan medicinal product designation by the European Medicines Agency. It is currently being evaluated in Phase II clinical trial to treat patients with phenylketonuria.
HMI-102 is an investigational gene therapy in clinical development for the treatment of phenylketonuria (PKU) in adults. HMI-102 is designed to encode the PAH gene, which is mutated in people with PKU, and delivered via the liver-tropic AAVHSC15 vector. Homology has received Fast Track Designation and orphan drug designation for HMI-102 from the U.S. Food and Drug Administration (FDA), and orphan drug designation from the European Medicines Agency (EMA). The company began the Phase I/II study of HMI-102 in 2019. The FDA held back the study over elevated liver function tests by a few months in 2022. In August 2022, the Company paused enrollment in the pheNIX gene therapy trial evaluating HMI-102, however the drug is currently active in the company’s pipeline in Phase I/II stage of development.
Phenylketonuria Pipeline Therapeutics Assessment
There are approx. 18+ key companies which are developing the therapies for Phenylketonuria. The companies which have their Phenylketonuria drug candidates in the most advanced stage, i.e. phase III include, PTC Therapeutics.
Request a sample and discover the recent advances in Phenylketonuria Ongoing Clinical Trial Analysis and Medications, click here @ Phenylketonuria Treatment Landscape
Scope of the Phenylketonuria Pipeline Report
Dive deep into rich insights for drugs for Phenylketonuria Market Drivers and Phenylketonuria Market Barriers, click here @ Phenylketonuria Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Phenylketonuria Mergers and acquisitions, Phenylketonuria Licensing Activities @ Phenylketonuria Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/